policy ·

CMO and TGA Issue Joint Warning on Unapproved Peptides

Australia's Chief Medical Officer and the TGA issue a joint statement declaring unapproved peptides a priority focus area for compliance enforcement.

TGACMOenforcementcompliancepublic-healthretatrutideBPC-157policy

Australia’s Chief Medical Officer Professor Michael Kidd and the Therapeutic Goods Administration have issued a joint statement warning that unapproved peptide products pose a “growing public health risk.” The statement, reported by Medical Forum on 25 June 2026, marks the first time Australia’s most senior medical official has publicly addressed the unregulated peptide market.

What the statement says

Professor Kidd said: “Unapproved peptide products pose a growing public health risk. Some of these products have not undergone sufficient human clinical trials and may cause significant harm. Australians should not use these products and should seek advice from their trusted healthcare professional.”

The statement follows a spate of adverse events including liver toxicity, severe allergic reactions, inflammation, and other health complications requiring medical attention. The Victorian Department of Health has reported six cases of acute liver toxicity associated with an unapproved peptide product labelled as retatrutide, as covered in our earlier report.

TGA designates unapproved peptides as priority focus area

Australia’s Acting Chief Medical Adviser Dr Amanda Cuss confirmed the TGA is actively monitoring and responding to potential non-compliance, including unlawful importation, supply, and advertising of therapeutic goods.

“Unapproved peptide products have been added as a priority focus area for the TGA compliance,” Dr Cuss said. “Where serious non-compliance is identified, the TGA may take regulatory action in line with its regulatory compliance framework.”

The designation as a “priority focus area” is significant. It signals that the TGA will allocate dedicated compliance resources to unapproved peptides, rather than treating them as part of general therapeutic goods enforcement. The TGA’s compliance framework includes infringement notices, seizure of goods, injunctions, and criminal prosecution.

Products specifically named

The joint statement named several compounds commonly found in unapproved products:

  • BPC-157 — a synthetic peptide marketed for tissue repair
  • GHK-Cu — a copper peptide promoted for anti-ageing
  • TB-500 — a synthetic version of thymosin beta-4
  • Retatrutide — a triple-agonist peptide in Phase III clinical trials
  • CJC-1295 — a growth hormone secretagogue

The TGA warned that counterfeit products are often deliberately designed to mimic genuine medicines, making it difficult for consumers to identify unsafe or potentially harmful goods. Many products are supplied as powders or injections in poorly labelled or unmarked vials, making it impossible to verify their ingredients or manufacturing safety.

Health practitioner guidance

The statement included specific guidance for health practitioners:

  • Be alert for patients with abnormal liver function tests or signs of acute liver injury
  • Ask patients presenting with these concerns about any peptide use, product name, and dose taken
  • Symptoms to watch for include tiredness or malaise, jaundice, abdominal pain, dark urine, and abdominal bruising

Health practitioners can report adverse events via the TGA’s adverse event reporting system and report counterfeit or unregulated products via the TGA’s product reporting portal.

What this means for the research community

The CMO’s involvement elevates the peptide enforcement discussion from a regulatory matter to a public health priority. For researchers and institutional procurement teams, the practical implications are:

  1. Supply chain scrutiny will intensify. Vendors supplying compounds named in the statement face increased enforcement risk. Researchers should verify that their suppliers have not received TGA compliance actions.

  2. COA requirements become more critical. The TGA’s warning about unmarked vials and unverifiable ingredients reinforces the need for batch-specific certificates of analysis from NATA-accredited laboratories.

  3. Advertising compliance matters more. The statement’s emphasis on counterfeit products designed to “mimic genuine medicines” suggests the TGA will scrutinise marketing language more closely. Vendors using therapeutic claims or implying human use may face enforcement action.

  4. Institutional policies should be reviewed. Universities and research institutions sourcing these named compounds should confirm their procurement policies align with the TGA’s heightened compliance expectations.

Sources

For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.